▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #837 by analyst upside · 2026-11-14
ZVRA
Zevra Therapeutics, Inc.
Healthcare · Market Cap $540M · P/E 7.4x
ANALYST PRICE TARGET
+161.6%
implied upside to consensus target
Current Price $9.08
Consensus Target $23.75
Bull Target $35.0
Bear Target $18.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
6
Hold
0
Sell
0
52-Week Low $8.01
52-Week High $15.04
YTD Return +8.9%
FUNDAMENTALS
Market Cap $540M
P/E Ratio (TTM) 7.4x
Forward P/E 10.2x
EPS (TTM) $1.22
PEG Ratio 10.67
Dividend Yield N/A
Revenue (TTM) $148M
Profit Margin 52.8%
52-WEEK RANGE
52-Week Low $8.01
52-Week High $15.04
Current Price $9.08
Bear Target $18.0
Bull Target $35.0
● Now $9.08 ● Target $23.75
TRADING DATA
Avg Volume 911K
YTD Return +8.9%
Analyst Count 8
Consensus Buy
Upside to Target +161.6%
Last Updated 2026-11-14

ANALYST SUMMARY

Zevra Therapeutics, Inc. (ZVRA) is currently trading at $9.08 with a Wall Street consensus price target of $23.75, implying potential upside of 161.6% over the next 12 months. 8 analysts currently cover ZVRA, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $35.0, while the most cautious has a target of $18.0.

ZVRA operates in the Healthcare sector with a market capitalisation of $540M. The stock is up 8.9% year-to-date and is currently trading near the lower end of its 52-week range of $8.01 – $15.04.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZVRA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Buy → Buy 2026-08-20 31% win rate (48 calls)
Guggenheim - Reiterated
Buy → Buy 2026-08-07 62% win rate (8 calls)
Citizens - Reiterated
Market Outperform → Market Outperform 2026-08-06 Building track record
Canaccord Genuity - Reiterated
Buy → Buy 2026-07-27 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-07-27 62% win rate (8 calls)
BTIG - Reiterated
Buy → Buy 2026-07-27 38% win rate (8 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-06-23 31% win rate (48 calls)
Canaccord Genuity - Reiterated
Buy → Buy 2026-06-11 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
44
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →